The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Approves Rituximab for Children with GPA & MPA

FDA Approves Rituximab for Children with GPA & MPA

October 23, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In late September, the U.S. Food and Drug Administration (FDA) approved rituximab (Rituxan) for treating granulomatosis with polyangiitis (GPA; formerly Wegener’s granulomatosis) and microscopic polyangiitis (MPA) in children aged 2 years and older. The treatment was approved as an injection and can be used in combination with glucocorticoids. This approval was made via priority review and received orphan drug designation status due to the unmet medical need. This is rituximab’s only pediatric indication.

You Might Also Like
  • Rituximab Receives Label Update for ANCA-Associated Vasculitis
  • FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients
  • FDA Approves Oral Methotrexate; Plus Restrictions for 2 Analgesics in Children
Explore This Issue
December 2019
Also By This Author
  • Ankylosing Spondylitis Patients Report Improved Quality of Life with Bimekizumab

In 2011, rituximab became the first and only FDA-approved therapy for treating adults with these two rare forms of vasculitis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Data
This approval of intravenous rituximab was based on data from the PePRS study, an international, phase 2a, multicenter, open-label, single-arm, uncontrolled study. The study examined the safety, pharmacokinetics, exploratory efficacy and pharmacodynamic outcomes of pediatric patients. During the clinical trial, 25 patients aged 6–17 years old with newly diagnosed or active GPA or MPA received four weekly infusions of rituximab or non-U.S.-licensed rituximab in combination with oral methlyprednisolone. Of the patients, six had MPA and 19 had GPA. Efficacy was primarily assessed using the Pediatric Vasculitis Activity Score (PVAS).

By Month 6, 56% of patients achieved PVAS remission. Additionally, 92% of patients achieved PVAS remission by Month 12, and 100% of patients achieved PVAS remission 100% by Month 18. The treatment’s safety profile in children was consistent with that of adult patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Rituximab is not indicated in children with GPA or MPA younger than 2 years old or in children with other conditions.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Genentech Inc. News release: FDA approves Genentech’s Rituxan (rituximab) in children with two rare blood vessel disorder. 2019 Sep 27.

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: giant cell arteritis (GCA), GPA, microscopic polyangiitis (MPA), rituximab, VasculitisIssue: December 2019

You Might Also Like:
  • Rituximab Receives Label Update for ANCA-Associated Vasculitis
  • FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients
  • FDA Approves Oral Methotrexate; Plus Restrictions for 2 Analgesics in Children
  • FDA Warns ‘Don’t Use Tramadol in Children’ & More

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.